Silence Therapeutics plc
SLN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 70.5% | 17.2% | 74.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 72.7% | 59.3% | 37.8% | 39.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -113.2% | -196.2% | -279.1% | -365.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -104.7% | -170.5% | -232.4% | -317.4% |
| EPS Diluted | -2.37 | -3.48 | -3.81 | -1.36 |
| % Growth | 31.9% | 8.7% | -180.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |